| 韩冬冬,顾康生.单药或联合方案二线治疗进展期胃癌研究进展[J].安徽医药,2018,22(12):2287-2290. |
| 单药或联合方案二线治疗进展期胃癌研究进展 |
| Advances in the study of second-line treatment of advanced gastric cancer with single drug or combined regimen |
| 投稿时间：2017-04-18 |
| DOI： |
| 中文关键词: 进展期胃癌 二线治疗 伊立替康 紫杉醇 |
| 英文关键词: Advanced gastric cancer Second-line therapy Irinotecan Paclitaxel |
| 基金项目: |
|
| 摘要点击次数: 2176 |
| 全文下载次数: 959 |
| 中文摘要: |
| 进展期胃癌的药物治疗随着时代发展取得一定进展。多项临床试验表明伊立替康或紫杉醇单药作为二线化疗可以提高进展期胃癌患者生存质量并延长生存时间,同时两药联合化疗方案、化疗联合靶向药物临床研究也在开展。但直到现在,标准的二线治疗方案仍有待确立。该文将对近几年进展期胃癌二线治疗的单药和联合方案临床研究进行汇总,希望能为二线治疗方案的选择提供参考。 |
| 英文摘要: |
| The medication of advanced gastric cancer has made some progress with the development of the times.A number of clinical trials have shown that irinotecan or paclitaxel as a second-line chemotherapy can improve the quality of life of patients with advanced gastric cancer and prolong survival time,meanwhile,clinical research of combined chemotherapy of the two drugs and chemotherapy combined with targeted drugs is also carried out.But until now,the standard second-line treatment program remains to be established.In this paper,we will summarize the clinical research of monotherapy and combination regimen of advanced gastric cancer in recent years,hoping to provide a reference for the choice of second-line treatment regimen. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
